New hope for kids with Hard-to-Treat blood disorder
NCT ID NCT07214025
Summary
This study aims to test the safety and effectiveness of a medication called romiplostim in children with chronic immune thrombocytopenia (ITP), a condition where the body attacks its own platelets. It will involve 100 children aged 1-18 who have not responded well to standard first-line treatments. The main goal is to see if the drug can safely and consistently raise platelet counts to a safer level over nearly a year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROMIPLOSTIM N01 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.